HanAll's Partner HBM Completes First Dosing of Phase 2 of Ba..
HanAll Biopharma
(KRX: 009420.KS) today announced that its partner for HL161(batoclimab) &
HL036(tanfanercept) for the Chinese market, Harbour BioMed, has received IND
approval for Phase 2 of batoclimab in patients with chronic inflammatory
demyelinating polyneuropathy(CIDP) in China. The company is now pursuing 5
autoimmune diseases including myasthenia gravis(MG), grave’s ophthalmopathy(GO),
adult immune thrombocytopenia(ITP), neuromyelitis optica spectrum disorder(NMOSD),
and chronic inflammatory demyelinating polyneuropathy(CIDP) in the region.
For more
information, please refer to the link below.
- HBM press release
link: https://www.harbourbiomed.com/news/164.html